⚕ GalenOps field
←

SITE002-0188

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE002 (USA) · Dr. Nolan
consented 2022-10-08

AEs
8
Serious
1
Dropout signal
–

Adverse events

moderate assessed

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-11-24 (study day 29); relationship: N

moderate assessed

Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-11-26 (study day 31); relationship: not assessed

severe serious assessed

Grade 4 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-04-11 (study day 167); relationship: N; serious criteria: life-threatening

moderate assessed

Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-04-25 (study day 181); relationship: not assessed

moderate assessed

Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-06-20 (study day 237); relationship: not assessed

mild assessed

Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-07-10 (study day 257); relationship: Y

mild assessed

Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-08-21 (study day 299); relationship: not assessed

severe assessed

Grade 3 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-11-15 (study day 385); relationship: not assessed

Data queries

No data queries.